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Summary
The identity of allogeneic peptide/major histocompatibility complex (MHC) complexes that
elicit vigorous T cell responses has remained an interesting problem for both practical and the-
oretical reasons. Although a few abundant MHC class I-bound peptides have been purified and
sequenced, identifying the unique T cell-stimulating peptides from among the thousands of
existing peptides is still a very difficult undertaking. In this report, we identified the antigenic
peptide that is recognized by an alloreactive bml anti-B6 T cell clone using a novel genetic
strategy that is based upon measurement of T cell receptor occupancy in single T cells. Using
lacZ-inducible T cells as a probe, we screened a splenic cDNA library in transiently transfected
antigen-presenting cells (APCs) and isolated a cDNA clone that allowed expression of the ap-
propriate peptide/Kb MHC complex in APC. The antigenic octapeptide (SWEFSSL) exactly
matched the consensus Kb MHC motif, but was surprisingly encoded by a non-ATG defined
translation reading frame. Furthermore, the abundance o£the naturally processed analog in un-
transfected cells was estimated to be <10 copies per cell. These results illustrate a novelstrategy
for identifying T cell-stimulating antigens in general and directly show that alloreactive T cells
can respond to rather rare peptide/MHC complexes. These results also suggest that the total
pool ofprocessed peptides expressed on the APC surface may include those generated by cryp-
tic translation of normally expressed transcripts.
T
he clonotypic up antigen receptor of T cells recog-
nizes peptide/MHC class I or class II complexes. Nor-
mally, T cells respond to foreign peptides presented by self-
MHC molecules. T cells, however, also respond to allogeneic
cells with a vigor that far exceeds normal responses to con-
ventional foreign antigens (see references 1-3 for reviews).
This response, referred to as the allogeneic response, in-
volves T cell recognition ofnonself, allogeneic MHC mole-
cules. Compared to foreign antigens that are recognized by
-1 in 105 T cells, alloantigens are recognized by up to -1
in 102 T cells. The high frequency of T cells responding to
allo-MHC antigens is the basis for rapid rejection of alloge-
neic transplants and for graft versus host disease. Under-
standing the molecular basis of alloreactivity is therefore
important, not only for manipulating T cell responses in these
clinically relevant cases, but also for understanding the na-
ture and recognition ofligands by the TCR in general.
Defining the ligands recognized by allogeneic T cells is
key to understanding alloreactivity. At the present time, it
is uncertain whether the individual responding T cells rec-
ognize nonself MHC molecules with or without peptides,
'Abbreviations used in this paper: CPRG, chlorophenol red (3-galactoside;
X-GAL, 5-bromo-4-chloro-3-indolyl (3-n-galactopyranoside.
and whether the MHC-bound peptides represent a small
set of highly abundant or rare sequences (3) . Of the three
examples where the actual peptides recognized by alloreac-
tive (4, 5) and xenoreactive T cells (6) have been identified,
the processed peptides were abundantly expressed by the
APC . For two of these peptides presented by the Ld and
the Qa-1 MHC molecules, the donor proteins were also
quite abundant (5, 7). No donor protein has yet been iden-
tified for the peptide presented by HLA-A2.1 MHC to xe-
nogeneic murine T cells (6). These results have therefore
favored the argument that alloreactivity is caused by T cells
that recognize abundant peptide/nonself MHC complexes
(8) . By contrast, analysis of panels of alloreactive T cells
specific for Kb or its Kbm mutant alleles has suggested that
distinct peptides are presented by allogeneic MHC. By
HPLC analysis of APC extracts, both the Rammensee and
Sherman groups showed that different peaks contained al-
loreactive T cell-stimulating peptides (9, 10) . Thus, allore-
activity could be attributed to recognition of many differ-
ent peptides presented by MHC that stimulate different sets
of T cells. This interpretation has, however, remained in-
conclusive because the T cell-stimulating peptide sequences
or their relative abundance in APC is unknown.
Identifying MHC-bound peptides that actually stimulate
1739
￿
J. Exp. Med. © The Rockefeller University Press " 0022-1007/95/12/1739/12$2.00
Volume 182 December 1995 1739-1750T cells is a daunting task. Biochemical purification of the
peptides is difficult, not only because MHC molecules dis-
play thousands of different peptides on the cell surface (11-
13), but also because individual antigenic peptides can rep-
resent only a few copies per cell (14, 15) . Nevertheless,
with remarkable efforts and sophisticated instrumentation,
several groups have succeeded in determining the sequence
of some T cell-stimulating peptides (4, 6, 14) . These pep-
tides, as well as those identified as simply MHC-bound
peptides in APC, are related by MHC allele-specific con-
sensus motifs and, where known, are derived from endoge-
nously synthesized proteins (12, 13, 16). The latter fact has
allowed an alternative strategy for identifying antigenic
peptides by isolating the gene that allows generation of the
T cell-stimulating peptide/MHC complexes in the APC.
Boon and colleagues were the first to isolate T cell-defined
tumor antigen genes by expression cloning (17, 18) . The
antigenic peptide can subsequently be identified by testing
the activity of synthetic peptides that match the consensus
motif (19) and/or by narrowing the antigenic activity in
deletion constructs (20) . We recently showed that expres-
sion-cloning strategies can be further generalized and im-
proved by (a) generating the peptide/MHC complexes by
transient rather than stable transfections, and (b) by using
single T cell assays as an exquisitely sensitive read-out of
peptide/MHC complexes generated in the APC (21, 22) .
In this report, we applied this expression cloning strategy
for identifying the T cell-stimulating antigens that are ex-
pressed by allogeneic cells. First, lacZ-inducible T cells spe-
cific for allogeneic peptide/Kb MHC complexes expressed
by wild-type B6 mice were generated in the congenic bml
(Kbmi) mice. By screening a spleen cDNA library in trans-
fected APC with these T cells as a single-cell probe, we iso-
lated a a-tubulin cDNA that allowed antigen/MHC-spe-
cific lacZ response in the T cells. Curiously, the antigenic
octapeptide JAL8 (SWEFSSL) was not located within the
open reading frame of the a-tubulin sequence, but it was
encoded at the vector/cDNA insert junction. Most surpris-
ingly, this antigenic peptide was a cryptic translation prod-
uct of this cDNA because it was encoded in a non-ATG-
defined translational reading frame. Transfecting APCs with
constructs containing an in-frame ATG as the translation
initiation codon, or the addition ofexogenous synthetic pep-
tide, allowed expression of high levels of the T cell-stimu-
lating peptide/Kb complex. In contrast to the high abun-
dance ofall previously identified allogeneic T cell-stimulating
peptides, the abundance of the naturally processed peptide
in Kb+ cell extracts was <10 copies per cell. These results
demonstrate that rare peptide/MHC complexes can stimu-
late alloreactive T cells, and that these methods are applicable
to the identification of unknown T cell antigens in general.
Materials and Methods
Cell Lines and Cell Culture.
￿
All cells were maintained in RPMI
1640 medium (Cellgro; Mediatech, Washington, DC) supplemented
with 2 mM glutamine, 1 mM pyruvate, 50 p.M (3-mercaptoetha-
nol, 100 U/ml penicillin, 100 fig/ml streptomycin, and 10% fetal
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bovine serum (Hyclone Laboratories, Logan, UT) at 37°C in 5%
C02/air. Kb-COS, Db-COS, and K89.7.5 (Kb-L) cells have been
described previously (20, 21). The T2-Kb cell line was a kind gift
from Dr. P. Cresswell (Yale University School ofMedicine, New
Haven, CT). EL4 (H-26
) cells were obtained from Dr. D. Raulet
(University of California, Berkeley, CA). EG7 (OVA-transfected
EL-4) was a kind gift from Dr. MJ. Bevan (University ofWash-
ington, Seattle, WA). HeLa cells (CCL 2.2) were obtained from
American Type Culture Collection (Rockville, MD), and the liver
tumor line Hepal was a kind gift from Dr. M. Nishimura, Na-
tional Cancer Institute, Bethesda, MD), and their Kb-expressing
derivatives were generated as described (21, 23) . Kb' Hepa 1 cells
were also stably transfected with JMAL9 or 44S1 constructs by
electroporation (20) . B3Z T cell hybrid is specific for OVA pep-
tide SL8 (OVA 257-264)/Kb complex and has been described
previously (20, 21).
Generation
￿
of LacZ-inducible bm l Anti-B6
￿
T Hybrrdomms.
C57BL/6 (B6) and its congenic strain B6.C-H26-'/Byj (bml)
mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). 2-4-mo-old bml mice were injected twice with 2 X 10'
B6 spleen cells intraperitoneally 7 d apart. Spleens of immunized
bml mice were removed 1 wk after the second injection, and the
CTL were enriched by coculture with fresh irradiated B6 spleen
cells and rat Con A supernatant (10). CTL were fused with the
lacZ-inducible fusion partner BWZ.36/CD8 as described earlier
(24). Hybridoma cells were screened for their responsiveness to
B6 spleen cells. Anti-B6, lacZ-inducible T cell hybrids were
cloned by limiting dilution, and stable subdones were used in
subsequent experiments.
Construction and Screening the cDNA Library.
￿
A unidirectional
cDNA library using mRNA from Con A+LPS-activated B6 spleen
cells was constructed in the BstXI/NotI sites of the mammalian
expression vector pcDNAI (Invitrogen, San Diego, CA). The
cDNA inserts were ligated to the vector using the BstXI/EcoRI
linker (5' GAATTCCACCACA 3') at the 5' end and primer/
linker oligodT/Notl (5' AACCCGGCTCGAGCGGCCGCT18
3') at the 3' end. Recombinant plasmids were selected by trans-
forming the MC1061/P3 competent bacteria in ampicillin and
tetracycline in L broth/agar. The bacteria representing the cDNA
library were divided into 15 different pools each comprising _105
CFU. For expression screens, aliquots ofDNA (100 ng/ml) pre-
pared from each bacterial pool were transiently transfected into
2 X 104 Kb-COS cells per well of96-well plates. 2 d later, 3 X 104
bm1BZ19.4 T cells were added to each well, and after overnight
incubation, cultures were stained with the 5-bromo-4-chloro-3-
indolyl (3-D-galactopyranoside (X-GAL) substrate as described
(21, 24). Positive pools were scored as an increase in average
number of "blue" lacZ+ T cells over the vector alone background
control, as shown in the photomicrographs in Fig. 2. The single
plasmid that was responsible for the positive signal was isolated by
screening sequentially smaller pools ofrecombinant bacteria from
the positive pool and repeating the transfection and T cell assays
with DNA isolated from each bacterial pool. The number of
CFU at each stage were estimated as, Iv2 (_5-10 X 104), Iv2.4
(_2 X 103), Iv2.4.2 (_100), Iv2.4.5.2 (_20), and Iv2.4.5.2.44 (1).
cDNA Expression Constructs.
￿
Restriction maps and sequence of
the isolated Iv44 cDNA were obtained by standard methods. The
Iv44 deletion constructs were prepared as follows: 44S1 was pre-
pared by removing the 3' 0.6-kb fragment from Iv44 plasmid be-
tween the internal and the flanking Sphl sites in the polylinker,
and then religating the large fragment. Similarly, the internal Clal
and the 3' flanking Xbal sites were used to remove the 0.86-kb
fragment from 1-kb 44S1, and the remaining 134-bp insert-vec-for fragment was filled in with klenow andreligated. For 44SBS1,
DNA from the 44SC1 construct was obtained by excising the 5'
flanking BamHI site in thevector, andthe internal 3' Smal site in
the insert and was cloned into the BarnHI/Smal sites of the
pEVRF1 vector (25). For RF1, RF2, and RF3 constructs, the
44SBS1 plasmid was cut at the EcoRI site at the vector-insert
junction and was filled in with Klenow. The insert fragment was
then removed by making a second cut at the internal Smal site at
the 3' end. This blunt fragment was then cloned into the Smal
sites of pEVKF0, pEVRF1, andpEVKF2 vectors that allowtrans-
lation in each readingframe, as described previously (20, 25).
Constructs for expressing MGDDSFNTF (K610), MFNTFF-
SET (Kb11), and MASVVEFSSL UMAL9) peptides were prepared
using complementary synthetic oligonucleotides encoding these
residues in the pcDNAI vector. In addition, the oligonucleotides
contained nucleotides complementary to restriction site over-
hangs (BstXI) at the 5' end, atermination codon, andthe Xbal site
overhang at the 3' end. MGDDSFNTF, 5' ATGGGAGGAGAT-
GACTCCTTCAACACCTTCTAGA3', MFNTFFSET, 5'ATG-
TCCTTCAACACCTTCAGTGAGACCTAGA3', MASVVEF-
SSL, 5'ATGAGTGTGGTGGAATTCTCCAGCCTGTAGA3' .
Fidelity ofall constructs was confirmed by nucleotide sequencing.
Transient DNA Transfections.
￿
Stable COS cell transfectants ex-
pressing Kb or Db were transiently transfected with CsCl purified
large scale or with mini prep plasmid DNAs by the DEAE-dex-
tran/chloroquin protocol, as described in detail previously (20).
Transfections were performedwith 3 X 104 COS cellsperwell in
96-well flat bottom tissue culture plates. Two days later, transfected
cellswere tested forthe expression ofspecific peptide/MHC com-
plexes by overnight coculture with 3-10 X 104 T cells. LacZ
response induced in activated T cells was measured as described
below.
T Cell Activation Assays.
￿
Peptide/MHCligand-specific T cell
responses were measured by the lacZ activity induced in the T
cells (24, 26). 3-10 X 104 T cells were cocultured overnightwith
2-5 X 104appropriate APC, (normalspleen cells, cell lines, or trans-
fected cells) with or without exogenouspeptides (synthetic or ex-
tracts) in 96-well plates. The ligand-induced T cell response was
determined using the lacZ substrate chlorophenol red (3-galacto-
side (CPRG), as described (20, 24). In each well of the 96-well
plate, the conversion of CPRG to chlorophenol redwas measured
at 595 and 655 ran as reference wavelength with a plate reader
(model 3550; Bio Rad Laboratories, Hercules, CA). Data shows
the mean absorbance ofreplicate cultures, and they are representa-
tive of at leastthree independent experiments.
Antibodies and Synthetic Peptides.
￿
Antibody inhibition assaywas
performedto confirm theMHCrestriction ofT cell hybrids. Briefly,
3 X 104EL4 or Kb-L cellswere incubatedfor 1 h with anti-Kb an-
tibody (Y3, ATCC, HB176) or anti-Dbantibody (B22.249.Rl; Ce-
dar Lane, CA) and bmlBZ19.4 cells (105 per well) were added.
Plates were incubatedovernight andT cell response was measured
as above. Solid-phase synthesis of ASVVEFSSL OAL9, 9 mer),
SVVEFSSL QAL8, 8 met), SIINFEKL (SL8), GILQPDGQM-
PSDKTIGGGDDSFNTFFSETGAGKHVPR (37 mer), MPSD-
KTIGGGDDSFNTFFSETGAGKHVPR (29 met), KTIGGG-
DDSFNTFFSETGAGKHVPR (25 mer), GGDDSFNTFFSE-
TGAGKHVPR (21 met), SFNTFFSETGAGKHVPR (17 met),
and FNTFFSET (8 met) were performed using an automated
synthesizer (model 421; Applied Biosystems, Inc., Foster City,
CA). Peptides were purified by HPLC, and their synthesis was
confirmedby mass spectrometry.
Extraction ofProcessed Peptides.
￿
Total acid soluble peptide pool
from EG7 or EL4 cells was extracted by TFA, as described (27,
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28). Briefly, 107-10' cells were washed with PBS, lysed in 2 nil
0.1% TFA in water, and homogenized by ultrasonication using a
Sonic Dismembrator (Fisher Scientific, Pittsburgh, PA). The ho-
mogenate was spun at 12,000 gfor 30 min. The supernatant was
passed through a 10-kD filter (Ultra Free-MC; Millipore Corp.,
Bedford, MA). The filtrate was dried in a vacuum centrifuge, re-
suspended in PBS, and analyzed for processed peptides in T cell
activation assays described above.
Results
Generation of Peptide/Kb-specific, LacZ-inducible T Cells.
Alloreactive T cells specific for the Kb MHC class I mole-
cule were generated by immunizing the congenic bml
mutant mice with the spleen cells of wild-type B6 mice.
These strains were chosen because the bml mutant mice
differ from the wild-type B6 mice in three amino acid sub-
stitutions within the Kb-1 MHC u chain alone, thus con-
straining the alloreactive bml anti-B6 T cell response to only
the wild-type Kb MHC (29). After in vitro enrichment, the
alloreactive T cells were fused with the BWZ.36/CD8 fu-
sion partner to derive lacZ-inducible, T cell hybrids (24).
Fig. 1 shows three representative T hybridoma clones re-
sponding to either the immunogen (B6 spleen) or to Kb+
cell lines. None of the T cells recognized T2-Kb cells that
express predominantly empty MHC class I molecules (30).
Hybridoma bm1BZ3 recognized an antigen shared by the
B6 spleen and Kb-COS cells, but absent on Kb L cells,
while hybrids bm1BZ18 and bmlBZ19 recognized anti-
gens shared by B6 spleen cells and Kb L cells, which were
absent in Kb-COS cells. Further evidence that Kb MHC
determined the responsiveness ofthese T cells was obtained
by demonstrating that only anti-Kb, but not anti-Db anti-
bodies, inhibited their response (Fig. 1 B). This was ob-
served when either EL-4 (Kb, Db) or Kb-L (Kb, H-2k) were
used as APCs. Hybridoma bmlBZ19.4 was chosen for use
as a single T cell probe because ofits low reactivity towards
Kb-COS cells that were used as recipient APCs to screen
for its cognate antigenic cDNA.
Isolation of the bmlBZ19.4 T Cell-stimulating Antigen Gene.
To identify the gene that could generate the T cell-stimu-
lating peptide/Kb complex, we screened a cDNA library
prepared from B6 spleen cells. Kb-COS cells were trans-
fected with pools of cDNAs clones in 96-well plates. 2 d
later, the transfected cells were assayedfor expression ofthe
peptide/Kb MHC complex that stimulated lacZ response in
individual bmlBZ19.4 T cells. Photomicrographs of repre-
sentative cultures in Fig. 2 show that compared to the vec-
tor alonebackground, a few lacZ+ blue T cells were present
in one ofthe cultures, and that their number increased dra-
matically upon transfecting Kb-COS cells with yet smaller
cDNA pools. By sequential sib-selection of cDNA pools of
decreasing size, a single plasmid DNA (Iv2.4.52.44) that
allowedstimulation ofthe bmlBZ19.4 T cellswas identified.
This cDNA clone (referred to as lv44) specifically stimulated
the T cells only upon transfection into Kb-COS, but not
when it was expressed in Db-COS or in parental COS cells
(see below and data not shown). We conclude that APCB
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expressing the Iv44 plasmid DNA generated the peptide/
Kb complex, and that this was most likely caused by the an-
tigenic peptide encoded within the cDNA insert.
Location of the Antigenic Peptide in the Iv44 cDNA.
￿
The
cDNA insert in Iv44 plasmid was 1 .6 kb in length. Partial se-
quence of ^300 nucleotides at both the 5' and 3' ends ofthe
insert showed that Iv44 was identical to the mouse a-tubulin
mRNA sequence (MUSTUBA6M, GenBank/EMBL ac-
cession no. M13441) . Iv44 cDNA, however, lacked the first
131 nucleotides of the full-length clone that included the
natural ATG start codon. Nevertheless, a truncated tubulin
polypeptide (414 versus 449 amino acids) could be gener-
ated from this cDNA using the second in-frame ATG codon
as a translation initiation codon (31, 32). Examination of the
et-tubulin sequence for the consensus Kb MHC-binding
motif (xxxx[F,Y]xx[I,L,M,V]) revealed nine peptide se-
quences, Kb1-9, which are schematically shown in Fig. 3
A. Using the indicated endonuclease restriction sites, we
prepared a set of deletion constructs that contained only
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(A) Response of bml anti-B6 T hybridomas bmlBZ.3, bmlBZ.18, and bm1BZ19 towards the indicated Kb+ cells: B6 spleen, Kb-trans-
fected human TAP mutant T2, mouse L- or monkey COS cells. 105 T cells were cocultured overnight with varying numbers ofindicated Kb+ cell lines
as APC. ThelacZ activity induced in the Tcells was measured by the conversion ofthe CPRG substrate to the chlorophenol red product. Absorbance at
595 nm was read in a 96-well plate reader. (B) Anti-Kb but not anti-Db mAbs inhibit bm1BZ19 response to either EL-4 (Kb, Db) cells or to the Kb-L
transfectant APC. 105 T cells were cultured overnight with 5 X 10° EL-4 or Kb-L cells in presence ofvarying dilution ofY3 (anti-Kb) or B22 (anti-Db)
ascites. LacZ response in activated T cells was measured as described above.
Kb1-7 (44S1), Kbl (44SC1) alone or with no Kb motifs at all
(44SBS1) . These constructs were transfected into Kb- or Db-
COS cells that were tested for their ability to stimulate
bm1BZ19.4 T cell response (Fig. 3 B-D). The T cell re-
sponse clearly required both the cDNA constructs and the
Kb MHC molecule because no T cell response occurred
when the same constructs were expressed in Db-COS cells.
The smallest active construct that contained a Kb1 motif
was 44SC1, but surprisingly, the construct 44SBS1, lacking
all but two residues of the Kb1 motif, was as active as the pa-
rental clone Iv44. This result indicated that none of the nine
Kb-binding motifs represented the bmlBZ19.4 T cell-
stimulating peptide. To directly test the activity of the Kbl
motif that was present in 44SC1, but was disrupted in
44SBS1, we prepared a mini-gene construct (Fig. 3 A, Kbl)
that encoded only the peptide PRAVFVDL_and the trans-
lational initiation methionine codon.-This construct was
clearly inactive (Fig. 3 C), and it ruled out the possibility
that the two Kb1 residues shared between 44SC1 andFigure 2 .
￿
Isolation of the bm1BZ19.4-stimulating cDNA clone Iv2.4 .5 .2.44 (Iv44) by expression cloning. The B6 spleen cell cDNA library was
screened by transient transfection into Kb-COS cells that were then assayed for theirAPC function with the lacZ-inducible bm1BZ19.4 T cells . Individ-
ual lacZ+ T cells were visualized byX-GAL staining as "blue" lacZ+ cells . Panels show representative cultures when Kb-COS cells were transfected with
cDNA library pools of decreasing complexity . Note that the number oflacZ+ T cells is related to the complexity of the cDNA pools estimated as Iv2
(-5-10 X 10^), Iv2.4 (^2 X 10 3), Iv2.4 .5 (^"100), Iv2.4 .5.2 (^20), and Iv2.4 .5 .2.44 (1) . The enrichment of Iv44 cDNA, estimated by the number of
blue cells observed, was^"10-fold at each step and 100-fold in the final step .
44SBS1 accounted for the antigenic activity of these two
constructs . Thus, the T cell-stimulating activity of Iv44
could notbe attributed to any of the consensusKb motifs in
the open reading frame of the insert, but nevertheless re-
quired the first 102 nucleotides of the 44SBS1 construct .
The bm1BZ19.4-stimulating Peptide Is a Cryptic Translation
Product of Iv44cDNA . Three different hypotheses could ac-
count for the bm1BZ19.4-stimulating activity ofthe44SBS1
construct . First, theT cell-stimulating peptide presentedby
Kb MHC could differ from the classical Kb consensus motif .
Indeed the lung tumor specific peptideFEQNTAQP bears
no relationship to the consensus Kb motif (xxxx[F,Y]xx-
[I,L,M]), yet it has been described as capable of being pre-
sented by Kb MHC and eliciting tumor-specific CTL re-
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sponses (33) . Second, the antigenic peptide couldbe encoded
by one of the other non-ATG-defined translational open
reading frames in the construct. This unconventional mecha-
nism has been observed to yieldT cell-stimulating peptide/
MHC complexes in several independent model systems
(17, 20, 34) . Finally, the peptide presented by Kb need not
have been encodedby the constructs at all, but instead, could
have resulted from induction ofyet another cellular gene in
transfected APC. In this case, the minimal 44SBS1 construct
would contain the transcription/translation-inducing activ-
ity for the induced antigen gene .
All attempts to localize the antigenic activity within the
open reading frame of the ot-tubulin insert in the 44SBS1
construct failed . First, noT cell response was detected withA Expression constructs:
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a panel ofoverlapping synthetic peptides that corresponded
to the entire a-tubulin open reading frame (Fig. 4 A, frame
a) in exogenous presentation assays, even at supraoptimal
100-11,M concentration (data not shown). Second, the mini-
gene constructs Kb10 and K611, encoding partial (xxxx-
[F]xxx) motifs that bind Kb MHC in vitro with nonconsen-
sus COOH-terminal anchor residues (35), (Fig. 4 A, Kb10
and K'11) were inactive. Third, the RF1, RF2, and RF3
constructs designed to allow translation of each ofthe three
reading frames of the insert sequence alone were also com-
pletely inactive (Fig. 4 C). Taken together, these results
strongly suggested that the antigenic activity of the 44SBSI
construct was not caused by the insert sequence alone, but
that it required both the insert and the vector sequences.
Examination of the sequence of the entire transcript of
44SBS1 in each of the three translational reading frames re-
vealed a peptide sequence at the vector/cDNA insert june-
0 .3
0 .2
0
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bm1BZ19.4 T cell-
stimulating activity of Iv44 maps
to the 5' 102 by fragment
(44SBS1 construct) and requires
Kb MHC. (A) Schematic repre-
sentation of cDNA clone Iv44,
its deletion constructs, and their
activity in stimulating the
bm1BZ19.4 T cell response. The
location ofconsensus Kb-binding
peptide motifs (xxxx[F,Y]xx-
[1,L,M,V]) is shown by open cir-
cles labeled Kbl-9. (B) The T
cell-stimulating antigenic activ-
ity requires Kb MHC and the 5'
102-bp fragment of 44SBS1
construct. Kb- or D6-COS cells
were transfected with varying
DNA amounts of the indicated
constructs. 2 d later, the presence
of peptide/MHC complexes was
detected by overnight incubation
with bmIBZ19.4 T cells. Data
show lacZ activity that was in-
duced in T cells and was mea-
sured by the CPRG assay.
tion that matched the consensus Kb motif (Fig. 4 A). This
sequence was indeed the bm1BZ19.4 T cell-stimulating an-
tigenic peptide. The mini-gene construct (JMAL9) encod-
ing only these residues (ASVVEFSSL) with a methionine
codon added for translation initiation was at least 100-fold
more active than either the Iv44 or 44SBS1 constructs (Fig.
4 D). This dramatic difference in endogenous presentation
activity is consistent with the known differences in the trans-
lational efficiencies of ATG versus non-ATG codons (20) .
Based on our recent analysis ofnon-ATG codons that allow
generation of peptide/MHC complexes (36), it is quite likely
that translation of the antigenic precursor is initiated at the
upstream TGG and/or GAT codons that are in-frame with
the antigenic peptide (Fig. 4 A, arrows) . Furthermore, the
generation of the T cell-stimulating peptide via cryptic
translation was not limited to transiently transfected DNAs,
but was also observed in stably transfected Hepal cells (Fig.a
b
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5 A) . Thus, in accord with previous findings (17, 20, 34,
36), cryptic translation products generate peptide/MHC
complexes both in transient and in stable transfections .
Conclusive proof that the "out-of-frame" JAL9 nucleo-
tides did encode the antigenic peptide was obtained with
synthetic peptides . By contrast to the synthetic peptides
representing the ATG-defined open reading frame of the
insert (Fig . 4 A, frame a), which were completely inactive,
both the nona (ASVVEFSSL) and the octa (SVVEFSSL) pep-
tides oftranslational frame c (Fig . 4 A), stimulatedbm1BZ19.4
T cells strongly (Fig . 5 B) . Note that the dose-response curves
show that these peptides were active at even picomolar con-
centrations, and that the 8 mer was 3-10-fold more active
than the 9 mer. These results are entirely consistent with
previous analyses of naturally processed peptides presented
by the Kb MHC (12, 28, 37, 38) . With the sole exception
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Figure 4 . (A) Nucleotide se-
quence and predicted translation
products of 44SBS1 construct .
Insert sequence (uppercase letters)
and its flanking pEVRF0 vector
DNA (lowercase letters) are shown
with each of three translational
reading frames (a-c) in single-let-
ter amino acid code . Linker nu-
cleotides for ligating the cDNA
to the vector are underlined .
The 5' flanking vector sequence
provided an in-frame ATG initi-
ation codon that is in-frame with
the a-tubulin open reading frame
in frame a. The asterisks indicate
termination codons, and vertical
arrows show the presence ofalter-
nate non-ATG initiation codons
that could be used for translating
the peptide shown in frame c
(36) . The residues encoded by
the oligo constructs JMAL9,
Kb10, and Kbll are indicated
within parentheses and by dashed
lines . An in-frame ATG codon
(M) was added to each mini-
gene construct to allow transla-
tion . (B-D) bmIBZ19 .4 T cell-
stimulating activity of 44SBS1 is
encoded in a non-ATG-defined
translational reading frame . Anti-
genic activity of the indicated
cDNA constructs was tested by
transient transfection into Kb-
COS cells, as described in legend
to Fig. 3 . Labeled curves show T
cell responses obtained with the
constructs shown in Fig. 4 A .
The RF1, RF2, and RF3 con-
structs were identical to 44SBS1,
except that the insert sequence
alone, without the junction se-
quence, was placed downstream
of an in-frame ATG codon (20,
25) . Because o£ the rather high
activity of the JMAL9 relative to
.01
￿
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￿
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￿
10
￿
100
￿
the Iv44 or 44SBS1 constructs,
the cultures were incubated with
the lacZ substrate for only 1 .5 h
rather than the usual 4 h .
of the tumor peptide FEQNTAQP (33), these peptides
conform to the consensus motif xxxx[F,Y]xx[l,L,M], and
exhibit T cell-stimulating activity at extremely low- con-
centrations . Other Kb-restricted T cells that recognize con-
ventional (B3Z, anti-OVA257-264 (SL8)/Kb) or allogeneic
KbMHC (bm1BZ18.5) did not recognize theJAL8 orJAL9
peptides (Fig. 5, C and D) . Similarly, none of eight other
bml anti-B6 alloreactive T cells tested recognized either
JAL8 orJAL9 peptides (data not shown) . We conclude that
the JAL8 octapeptide is a cryptic translation product pre-
sented by Kb MHC, and that it serves as a unique ligand for
bmlBZ19 .4 T cells .
Relative Abundance of the Naturally Processed Peptide/K'
Complex in NormalAPC . What is the abundance ofthe nat-
urally processed counterpart ofJAL8 peptide? While the
DNA constructs and the synthetic peptides allowed genera-o+
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tion of the bm1BZ19.4-stimulating complex, a similar com-
plex was naturally expressed by normal B6 spleen cells as
well as by otherKb+ cell lines (Fig . 1, A and B) . To analyze
this naturally processed peptide, we extracted the total pool
of processed peptides from EL-4 (H-26) and its OVA-
expressing derivative, EG-7 (39) . Because EG-7 cells ex-
press the OVA-derived SL8/Kb complex, the presence and
amount of naturally processed SL8 peptide in the extracts
provides a critical internal control. While both B3Z and
bmlBZ19.4 T cells were capable of responding to similarly
low concentrations (-1-3 pM) of the synthetic SL8 and
JAL8 peptides, respectively (Fig. 6 A), only the naturally
processed SL8 peptide was detected in extracts of EG-7
cells (Fig . 6 C) . No bm1BZ19.4-stimulating activity was
detected in either EL-4 or EG-7 extracts (Fig. 6 B) or in
extracts of five B6 spleens (data not shown) . From the sen-
sitivity ofthe assay for detecting syntheticJAL8 peptide, we
estimate that the abundance of the naturally processedJAL8
counterpart in EL-4 or in normal spleen cells is less than
eight copies per cell . This estimate was validatedby the fact
that the same EG-7 extract yielded 90 SL8 copies per cell.
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Figure 5. bmlBZ19.4 T cell-stimulating ligand is
generated in (A) stable Kb' hepatoma (Hepal) transfec-
rants expressing either 44S1 or JMAL9 constructs, and
in (B) Kb-COS, but not Db-COS, incubated with syn-
thetic peptides corresponding to the cryptic translation
products. (C and D) JAL9 or JAL8 are not recognized
by either bm1BZ18 .5 (bml anti-Kb) or B3Z (anti-
OVA/Kb) T cells . Amino acid sequences of synthetic
peptides JAL9 and JAL8 are shown in single letter
10
￿
105 ￿code . T cell responses were measured by the CPRG
assay for lacZ activity as described in the legend to Fig .
1 . See Materials and Methods for details.
Remarkably, our result is virtually identical to the completely
independent estimate of 88 SL8 copies/EG-7 cell by Ram-
mensee's group (40) . Thus, the natural peptide/Kb complex
recognized by bmlBZ19.4 T cells is expressed at a very
lowlevel in Kb-expressing cells .
What is the source of the naturally processedJAL8 ana-
logue in untrans£ected Kb-APC? A match for the JAL8
peptide sequence was not found in either the protein (Swiss-
Prot release 37 .0) or nucleic acid (GenBank/EMBL release
86.0) databases . Note that because peptides with amino acid
substitutions can cross-react with T cells (41, 42), and that
the low abundance of the naturally processed peptide in
cell extracts precluded comparison ofjAL8 peptide with its
natural analogue by HPLC (28, 43), it is uncertain at this
time whether the naturally processed peptide is identical to
JAL8, and whether it is derived from a normal cellular pro-
tein or via cryptic translation ofan alternate reading frame.
Discussion
The bml anti-B6 alloreactive bmlBZ19.4 T-cells rec-
ognize the octapeptide SVVEFSSL (JAL8)/Kb complex.a
Q
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N d
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TheJAL8 peptide was identified by a novel genetic strategy
for isolating cDNAs that allow expression of the T cell-
stimulating complex in transfected APCs . Surprisingly, the
JAL8 peptide was a cryptic translation product ofthis cDNA
clone and its natural counterpart was present at <I 0 copies
per cell in APCs . These results show that as for normal T
cell responses to foreign antigens, alloreactive T cells can re-
spond to rare peptide/MHC complexes .
The explanation forwhy allogeneicMHC molecules elicit
vigorous T cell responses has remained elusive for decades .
Early hypotheses (44), proposing structural or functional dif-
ferences among TCRs expressed by alloreactive versus con-
ventional antigen-specific T cells are currently less attrac-
tive, and attention has focused instead on the MHC ligands
for the TCR (3) . Strong evidence that peptides play a criti-
cal role in alloreactivity is now available with mutant cells
that express emptyMHC molecules on their surface, and are
consequently not recognized by alloreactive T cells (e.g .,
Fig . 1) unless processed peptides from wild-type cells are
added exogenously (9, 10, 45) . Interestingly, each of the
two allogeneic and one xenogeneic peptide/MHC com-
plexes that have been characterized so far appear to be ex-
pressed as thousands o£ copies on APC surface (4-6) . Based
on the high level of expression ofthese peptides and the es-
timates of the frequency ofT cells that recognize them, it
has been argued that alloreactive T cells are primarily stim-
ulated by abundant peptide/MHC complexes (8) .
Identification ofJAL8 peptide allowed us to estimate the
level of expression of its naturally processed counterpart in
APCs . Similar to all naturally processed peptides character-
ized so far, synthetic JAL8 peptide was active in stimulating
bm1BZ19.4 T cells at low picomolar concentrations (Figs .
5 and 6) . In contrast to the B3Z-stimulating SL8 peptide that
was expressed at^100 copies inEG-7 cells, the bm1BZ19.4-
stimulating peptide was expressed below the detection thresh-
old of 10 copies in the same extracts . This low level of ex-
pression is at the extreme end ofthe range recently established
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Figure 6 . Analysis of naturally
processed T cell-stimulating pep-
tides in APC extracts. (A) Both
bm1BZ19.4 and B3Z detect their
cognate JAL8 and SL8 synthetic
peptides with comparable sensitiv-
ity . (B) No bm1BZ19 .4 stimulat-
ing, but only (C) B3Z stimulating,
processed SL8 peptide is detected
in cell extracts. Varying amounts of
synthetic peptides or 0.1% TFA
extracts ofparental EL-4 cells or its
OVA-expressing derivative, EG-7
cells, were incubated with Kb
10
￿
100
￿
HeLa cells as APC and theT cells.
After overnight culture, lacZ re-
sponse induced inT cells was mea-
sured as described in the legend to
Fig. 1 .
for the minimum number ofpeptide/MHC complexes that
are required for T cell stimulation (15) . Interestingly, simi-
lar low levels ofpeptide expression (<30 copies per cell) were
also estimated for expression of the processed OVA257-264
(SL8) peptide when it was generated as a cryptic translation
product from experimental constructs (36) . Thus, barring
the unlikely but formal possibility that the natural analogue
ofJAL8 peptide is exceptional in being active only at very
high concentrations, APCs express rather low levels of the
bm1BZ19.4-stimulating peptide . Furthermore, the fact that
of the eight bm1 anti-B6 hybrids that were tested, only
bm1BZ19.4 cells were stimulated byJAL8/Kb complex sug-
gests that a diverse set of peptides are actually presented by
allogeneicMHC molecules to a correspondingly diverse set
of alloreactive T cells, fulfilling early predictions (1), and
explaining the high frequency and vigor of alloreactive T
cell responses .
It is interesting to contrast the peptide purification and
our expression-cloning approaches to account for conflict-
ing conclusions on the abundance of peptides recognized
by alloreactive T cells . Because success of peptide purifica-
tion depends on isolatable amounts of processed peptides
expressed in the target cells, a correlation between peptide
abundance and ease ofits purification is expected. By con-
trast, the antigenicJAL8 peptide was identified using an ex-
pression cloning strategy that depends on the generation of
MHC-bound peptides derived from the transfected donor
gene in the APCs at a level sufficient to stimulate T cells . In
addition to the differences in the mechanism (exogenous
versus endogenous) for generation of the peptide/MHC
complexes, we also used an exquisitely sensitive single T
cell activation assay as a probe for ligand expression (21,
26) . Thus, as demonstrated previously with model antigens
(20, 21, 24), and here with the JAL8 peptide, rare peptide/
MHC complexes may be more accessible by the expres-
sion-cloning methods described here . Furthermore, it is
possible that different immunization procedures may favorselection of T cells that respond to abundant or rare ligands.
This is particularly relevant to xenogeneic immunizations
where species-specific differences in MHC/CD8 corecep-
tor interactions markedly influence T cell responses (46).
Future discoveries of other alloreactive T cell-stimulating
antigens, particularly those presented by the same MHC
molecule, are needed to clarify this issue.
The unexpected finding that JAL8 peptide was a cryptic
translation product and was expressed in APC raises the is-
sue of the source of peptides for display by MHC. Un-
doubtedly, MHC bind and present peptide fragments that
are obtained from intracellular polypeptides (47) . It is not
clear, however, whether these peptides are solely byprod-
ucts of cellular protein turn-over or are also generated via
alternate mechanisms. Intriguing observations in several ex-
perimental systems have demonstrated that peptide/MHC
complexes are generated from donor genes that should not
have been expressed (17, 20, 34). Boon and his colleagues
were the first to formulate the "pepton" hypothesis ex-
plaining how gene fragments lacking obvious transcrip-
tional promoters or translational control sequences could
yield peptide/MHC complexes (48) . Subsequent analysis
from this laboratory showed that the generation of these
peptides could be explained by cryptic translation initiated
by non-ATG codons (20). By screening DNA constructs in
APCs for their ability to generate T cell-stimulating pep-
tide/MHC complexes, we identified the set of non-ATG
translation initiation codons, and we determined that de-
spite being below detection levels in cell extracts, the amount
of these cryptic translation products in either transiently or
stably transfected APC were sufficient to cause T cell acti-
vation (36). The fact that JAL8 peptide is a cryptic transla-
tion product of lv44 cDNA and that it was initially identi-
fied in a complex cDNA mixture (Fig. 2) provides strong
independent support to the notion that peptide/MHC com-
plexes in APCs can be generated by cryptic translation.
Presentation of cryptic translation products can have a
significant impact on the diversity of peptides displayed by
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